anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses PLGA nanoparticles loaded with melittin and astaxanthin simultaneously and application thereof. Belongs to the technical field of nano medicine carrying. The PLGA nanoparticle disclosed by the invention comprises the following components in parts by weight: 10 parts of melittin, 100 parts of polylactic acid-glycolic acid copolymer, 450 parts of polyvinyl alcohol, 500 parts of chitosan and 30 parts of astaxanthin. Compared with the prior art, the invention has the beneficial effects that: (1) Melittin itself has very strong sensitization, such as hemolysis, and after nanocrystallization, the hemolysis is significantly reduced. (2) Astaxanthin itself is poorly soluble in water, unstable in air, and has a fishy smell. After being coated by the nano-carrier, the water solubility and the cell compatibility of the nano-carrier can be greatly improved.
The utility model discloses a medicine structure with a mixed adhesive layer. The medicine structure gives prominence to that the medicine has at least more than two separate unit layers, and the separate unit layers respectively have the ginsenoside and the lecithin serving as the main component. The adjacent connecting surface of each two separate unit layers has an adhesive layer. The separate unit layers are adhered and connected into integration through the adhesive layer and are packed in the casing by an outer casing. The change of the shape of the medicine itself has very obvious prompt function, which not only distinguishes the respectively separate part of the Chinese patent medicine of the medicine, but also marks the weight percentage of each separate part. In the aspect of preventing and striking the counterfeit and shoddy products, the utility model provides an analogous and referential product manufacture mode and an industrial standard for realizing the mode for all the pharmacy trades.
PURPOSE:To provide the titled antismoking agent which enables the stopping or saving of smoking relatively easily, without causing the withdrawal symptoms, by using a mixture of pine resin extract and an organic germanium compound or a substance containing an organic germanium compound as a base. CONSTITUTION:The objective antismoking agent having antinicotinic property is prepared by mixing (A) a pine resin extract obtained by adding an organic solvent (e.g. ethyl ether) to natural pine resin, leaving the mixture in a sealed vessel for about 24 hours, and evaporating the ethyl ether used as the solvent, with (B) 0.1wt%, based on said extract, of an organic germanium compound. The agent is preferably compounded further with licorice extract, caramel, etc. to facilitate the oral administration, and with vitamin B2, vitamin B6, Vitamin C, etc. to improve its antinicotinic property. The harm of smoking can be remarkably decreased by the synergistic effect of the antinicotinic property of the components.
Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
Participants will be selected from 3 local oculoplastics surgeons' procedural slates during the study period. Eligible participants are those who will be undergoing bilateral eye procedures. They will be randomized into one of two groups: Group A will receive tapping on their forehead for their first eye injection of local anesthesia, and then vibration to their forehead for the second eye. Group B will receive the reverse. Pain scores will be aggregated and an average taken to help determine which method is superior. The vibration assist device (variety of facial massagers are available on Amazon for roughly $16-20CDN) is being considered in addition to the current standard of tapping or no tactile distraction at all during the injection of local anesthetic. The 11-point pain Visual Analog Scale will be used to help grade pain experience after each eye is frozen. To help qualify, if there is a difference, the patient will be asked if they felt one technique was better than the other by a little, quite a bit, or a lot.
Compositions for dyeing keratin fibers are described. Said dyeing compositions comprise, in a cosmetically acceptable medium, based on the total weight of the composition: (a) at least one anionic surfactant, (b) at least one cationic surfactant; (c) at least one alkoxylated C 6 -C 24  fatty alcohol; (d) at least one C 6 -C 24  fatty alcohol; (e) at least one oxidation dye, (f) about 0.1-10 wt. % of ammonia; wherein the compositions do not comprise more than 2 wt. % of alkanolamines, C 1 -C 4  alkyl alkanolamines, or any fatty acid salt thereof, or mixtures thereof. These dyeing compositions present reduced ammonia odor and, at the same time, a faster color processing. A process for preparing these compositions, a process for permanent dyeing keratin fibers using these compositions and a packaging kit containing these compositions are also described.
In the soy isoflavone group, patients took 100 mg soy isoflavone in the form of two tablets per day for 12 weeks along with lifestyle modification. Each soy isoflavone 50 mg tablet contained 1.49 mg of genistein, 31.86 mg of genistin, 1.75 mg of daidzein, 13.21 mg of daidzin, 0.55 mg of glycitein and 1.14 mg of glycitin. The soy isoflavone tablets were made by Gol Daru Pharmaceutical Company, Isfahan, Iran.
Compositions and methods for administration of a bio-affecting catalyst, such as an enzyme, are provided. The compositions comprise at least one enzyme or other bio-affecting catalyst, retained within a matrix. The matrix provides a barrier between the entrapped enzyme and external degradative enzymes or cellular defense systems of a patient's body, and also prevents release of the enzyme. The matrix comprises pores or channels to enable entry and exit of substrates and products. Preferably, the matrix is a high viscosity cubic phase of one or more suitable amphiphilic compounds, such as glyceryl monooleate. Preferred methods of the invention comprise formulating the composition as an injectable low viscosity phase, which undergoes phase transition upon exposure to physiological conditions.
Focalin XR is for oral administration once daily in the morning.

Focalin XR may be swallowed as whole capsules or alternatively may be administered by sprinkling the capsule contents on a small amount of applesauce (see specific instructions below). Focalin XR and/or their contents should not be crushed, chewed, or divided. 

The capsules may be carefully opened and the beads sprinkled over a spoonful of applesauce. The mixture of drug and applesauce should be consumed immediately in its entirety. The drug and applesauce mixture should not be stored for future use.

Dosage should be individualized according to the needs and responses of the patient.
Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea). Fennel seeds (2 grams) were put into 150 ml water, boiled at a temperature of 100 °C, and left for 20 minutes. Women were then instructed to drink the tea. Bowel sounds were recorded every 2 hours, before and after drinking the fennel tea. The time of the first flatulation and the first bowel sounds were determined by asking the women themselves and this information was then recorded using the study form.
<P>PROBLEM TO BE SOLVED: To develop and provide a pharmaceutical agent for improving diseases or tissue conditions accompanied by reduction of the amount of collagen in tissues.  <P>SOLUTION: 1. The composition for promoting accumulation and/or suppressing reduction of collagen comprises a triazinoindolamine compound represented by formula (I) (wherein X represents H, an alkyl group or the like; Y represents H, an alkyl group or the like; Z represents a 1-2C alkylene chain which may be substituted with a 1-3C alkyl group; R represents an alkyl group, an alkoxy group or the like) or a pharmaceutically acceptable salt thereof. 2. The method for promoting accumulation and/or suppressing reduction of the amount of collagen includes a process for administering an effective amount of the triazinoindolamine compound expressed by formula (I) or the pharmaceutically acceptable salt thereof to nonhuman mammals able to be diagnosed to have diseases or tissue conditions accompanied by reduction of the amount of collagen in the tissue.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Biostructures that comprises modified alginates entrapping one or more stem cells are discloses. The modified alginates comprise at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide. Pluralities of stem cells are also disclosed. Methods of preventing death of stem cells and cells differentiated there from are disclosed. Methods of preparing a plurality of stem cells are disclosed. Methods of treating an individual who has a degenerative disease, such as a neurological disorder, or injury involving nerve damage by administering stem cells to said individual are disclosed.
The effectiveness of PROVIGIL in improving wakefulness in patients with excessive sleepiness associated with SWD was demonstrated in a 12-week placebo-controlled clinical trial. A total of 209 patients with chronic SWD were randomized to receive PROVIGIL 200 mg/day or placebo. All patients met the criteria for chronic SWD. The criteria include: 1) either, a) a primary complaint of excessive sleepiness or insomnia which is temporally associated with a work period (usually night work) that occurs during the habitual sleep phase, or b) polysomnography and the MSLT demonstrate loss of a normal sleep-wake pattern (i.e., disturbed chronobiological rhythmicity); and 2) no other medical or mental disorder accounts for the symptoms, and 3) the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g., time zone change [jet lag] syndrome).

It should be noted that not all patients with a complaint of sleepiness who are also engaged in shift work meet the criteria for the diagnosis of SWD. In the clinical trial, only patients who were symptomatic for at least 3 months were enrolled. 

Enrolled patients were also required to work a minimum of 5 night shifts per month, have excessive sleepiness at the time of their night shifts (MSLT score < 6 minutes), and have daytime insomnia documented by a daytime polysomnogram.

The primary measures of effectiveness were 1) sleep latency, as assessed by the MSLT performed during a simulated night shift at the final visit and 2) the change in the patient’s overall disease status, as measured by the CGI-C at the final visit [see Clinical Studies (14.1) for a description of these measures.]. 

Patients treated with PROVIGIL showed a statistically significant prolongation in the time to sleep onset compared to placebo-treated patients, as measured by the nighttime MSLT at final visit (Table 2). A statistically significant greater number of patients treated with PROVIGIL showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3). 

Daytime sleep measured with polysomnography was not affected by the use of PROVIGIL.
PROBLEM TO BE SOLVED: To produce a zinc oxide particle compsn., preferably a superfine zinc oxide particle compsn. with a high density coating comprising oxide of silicon on the surface of each particle and to obtain cosmetics contg. the compsn. SOLUTION: An aq. suspension of zinc oxide particles, preferably superfine zinc oxide particles having <=0.15 μm average particle diameter is prepd., a water-soluble silicate is added to the suspension by 1-50 wt.% (expressed in terms of SiO2 ) based on the weight of zinc oxide and the suspension is neutralized to pH 6.0-8.0 by adding an acid over >=40 min while keeping the temp. at a temp. of >=60 deg.C. high density coatings comprising oxide of silicon are formed on the surfaces of the zinc oxide particles by 1-50 wt.% based on the weight of zinc oxide and the objective compsn. having <=2 ppm (expressed in terms of Zn) solubility to pure water and <=20 ppm (expressed in terms of Zn) solubility to 0.0005 wt.% aq. sulfuric acid soln. is obtd.
Type 2 diabetes mellitus (T2DM) can lead to multiple complications. T2DM-related bone damage has been linked to abnormal bone turnover, but it cannot fully explain the mechanisms of T2DM bone disease. This study attempts to elucidate the underlying mechanisms of poor bone quality in T2DM. Hence, T2DM model was induced by a high-fat diet combined with a single streptozotocin injection in 7-week-old male SD rats. Osteoblasts derived from SD rats were cultured in high glucose to mimic hyperglycemia. Low bone turnover was observed in T2DM bone with elevated levels of advanced glycation end-products (AGEs) and receptor for AGEs (RAGE). Additionally, higher levels of oxidative stress and inflammatory factors were found in T2DM bone. AGEs content in bone was pairwise correlated with RAGE, hydrogen peroxide, and inflammatory factors. Serum levels of RAGE, oxidative stress, and inflammatory factors were higher in T2DM, while AGEs content tended to be lower. Besides, 35 differentially expressed metabolites were screened in T2DM serum. Osteoblasts exposed to high glucose displayed analogous abnormal changes in these biomarkers. Thus, low bone turnover in T2DM might be partially due to excess oxidative stress and inflammation induced by AGE-RAGE signaling. Furthermore, these biomarker levels in serum were mostly consistent with bone, demonstrating their possibility for predicting bone quality in T2DM.
Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
BACKGROUND AND STUDY AIMS: The aim of this study is to explore the risk factors for parenteral nutrition-associated liver disease (PNALD) in patients with severe acute pancreatitis by establishing a verification risk model.
PATIENTS AND METHODS: A total of 176 patients with severe acute pancreatitis from January 2019 to August 2021, were assigned into the observation group (n = 88) and control group (n = 88) based on the diagnostic results of PNALD, randomly. Their clinical data were recorded. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and alkaline phosphatase (ALP), etc., were detected. The logistic model and desicion tree model were used to analyze the risk factors.
RESULTS: Patients in the observation group had higher levels of ALT, AST, TBIL, and lower level of ALP than those of control group (P < 0.05). Multivariate logistic regression analysis revealed that alcohol intake history, ALT ≥69.65 U/L, AST ≥71.27 U/L, TBIL ≥26.27 μmol/L and ALP ≤45.11 U/L were risk factors for PNALD. The levels of ALT and AST in observation group were two times as high as those in the control group, which conformed to the Danan's criteria and accorded with the results of univariate analysis.
CONCLUSION: The regression model showed high consistency with the decision tree model in the prediction of risk factors. Alcohol intake history, ALT ≥69.65 U/L, AST ≥71.27 U/L, TBIL ≥26.27 μmol/L and ALP ≤45.11 U/L are risk factors for PNALD.
Colorectal cancer (CRC) is the third most prevalent cancer worldwide. Current studies have demonstrated that tumor-derived extracellular vesicles (EVs) from different cancer cell types modulate the fibroblast microenvironment to contribute to cancer development and progression. Here, we isolated and characterized circulating large EVs (LEVs), small EVs (SEVs) and non-EV entities released in the plasma from wild-type (WT) mice and the APCMin/+ CRC mice model. Our results showed that human colon fibroblasts exposed from APC-EVs, but not from WT-EVs, exhibited the phenotypes of cancer-associated fibroblasts (CAFs) through EV-mediated NF-κB pathway activation. Cytokine array analysis on secreted proteins revealed elevated levels of inflammatory cytokine implicated in cancer growth and metastasis. Finally, non-activated cells co-cultured with supernatant from fibroblasts treated with APC-EVs showed increased mRNA expressions of CAFs markers, the ECM, inflammatory cytokines, as well as the expression of genes controlled by NF-κB. Altogether, our work suggests that EVs and non-EV components from APCMin/+ mice are endowed with pro-tumorigenic activities and promoted inflammation and a CAF-like state by triggering NF-κB signaling in fibroblasts to support CRC growth and progression. These findings provide insight into the interaction between plasma-derived EVs and human cells and can be used to design new CRC diagnosis and prognosis tools.
If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin cream, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.
Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
SMAD4 is a tumor suppressor mutated or silenced in multiple cancers, including oral cavity squamous cell carcinoma (OSCC). Human clinical samples and cell lines, mouse models and organoid culture were used to investigate the role that SMAD4 plays in progression from benign disease to invasive OSCC. Human OSCC lost detectable SMAD4 protein within tumor epithelium in 24% of cases, and this loss correlated with worse progression-free survival independent of other major clinical and pathological features. A mouse model engineered for KrasG12D expression in the adult oral epithelium induced benign papillomas, however the combination of KrasG12D with loss of epithelial Smad4 expression resulted in rapid development of invasive carcinoma with features of human OSCC. Examination of regulatory pathways in 3D organoid cultures of SMAD4+ and SMAD4- mouse tumors with Kras mutation found that either loss of SMAD4 or inhibition of TGFβ signaling upregulated the WNT pathway and altered the extracellular matrix. The gene signature of the mouse tumor organoids lacking SMAD4 was highly similar to the gene signature of human head and neck squamous cell carcinoma. In summary, this work has uncovered novel mechanisms by which SMAD4 acts as a tumor suppressor in OSCC. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Purpose: The purpose of the research is to learn more about how low blood sugar (low blood glucose or hypoglycemia) affects the way the blood vessels work in healthy people. Subjects who participate in this research project must be in good health and taking no medications.

Methods: A screening visit to the Clinical Research Center of the Ohio State University will be used to assess eligibility to participate. The main study consists of two visits to the Clinical Research Center that occur two to four weeks apart. Each of these visits will involve a procedure known as an insulin clamp. This involves giving insulin and sugar water into a vein. The amount of sugar given varies to keep the blood sugar at a predetermined level. For one of the two visits the blood sugar will be low and the other it will be normal. The function of the blood vessels will be measured three times during each study by measuring blood flow before and after stopping blood flow to the arm for 5 min.
Risk Summary

Orthoebolavirus zairense infection is life-threatening for both the mother and fetus and treatment should not be withheld due to pregnancy (see Clinical Considerations). Available data from the PALM trial and an expanded access program in which pregnant women with Orthoebolavirus zairense infection were treated with INMAZEB demonstrate the high rate of maternal and fetal/neonatal morbidity consistent with published literature regarding the risk associated with underlying maternal Orthoebolavirus zairense infection. These data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome. Animal reproduction studies with INMAZEB have not been conducted. Human monoclonal antibodies, such as INMAZEB, are transported across the placenta; therefore, INMAZEB has the potential to be transferred from the mother to the developing fetus.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk 

Maternal, fetal and neonatal outcomes are poor among pregnant women infected with Orthoebolavirus zairense. The majority of such pregnancies result in maternal death with miscarriage, stillbirth, or neonatal death. Treatment should not be withheld due to pregnancy.
The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
BACKGROUND: Patients with a dual-diagnosis of epilepsy and dissociative seizures (DS) have received far less attention than those with single pathology. Anti-seizure medication (ASM) prescription patterns and safety of rationalisation have not been reviewed.
METHODS: We undertook a retrospective cohort study of all patients with a dual-diagnosis admitted to the Scottish Epilepsy Centre between 2012-2020. ASM frequencies were compared across admission, discharge and follow-up and emergency hospital attendances compared a year before and after admission. Demographic data, seizure characteristics and mortality data were also reviewed.
RESULTS: Across the 139 patients included in our study, ASM frequency at follow-up was significantly lower than on admission (mean 2.51 vs 2.14, Z = -2.11 p = 0.035, r = -0.215). Total hospital attendances in the year following admission were significantly lower than in the year before (mean 1.27 vs 0.77, Z = 2.306, p = 0.021, r = -0.262). Those with inactive epilepsy had their medications reduced to a greater extent that those with active epilepsy. 44 patients had their ASM frequency reduced during admission with a similar trend of reduced hospital attendances (mean 1.29 vs 0.43 Z = -3.162 p = 0.002). There was one epilepsy related death.
CONCLUSIONS: Clinicians should consider the development of co-morbid DS in patients with epilepsy not responding to an escalation of ASM, especially if presenting with a new seizure type. Patients with a dual-diagnosis of epilepsy and DS, particularly those with well controlled epilepsy, are likely overtreated with ASM. Medication review in a tertiary epilepsy centre allows for safe rationalisation of ASM and likely contributes to the need for fewer hospital attendances.